U.S. cancer researchers say a vaccine for treating a recurrent brain cancer known as glioma has shown promising results in preliminary clinical trials.
Findings from the first group of six patients in the study -- being conducted at the University of California-San Francisco's Brain Tumor Research Center -- involved vitespen (trademarked as Oncophage), a vaccine made from the patient's own tumor.
The trial's preliminary results indicate the vaccine was associated with tumor-specific immune response in patients with recurrent, high-grade glioma.
Glioma is a type of primary tumor that arises from the glial cells -- the connective tissue cells that surround and support nerve cells. The most common site of involvement of a glioma is the brain. Malignant glioma is currently a fatal disease.
"This is the first documentation of a glioma-specific immune response after vaccination with vitespen," said Dr. Andrew Parsa, assistant professor in the University of California-San Francisco Department of Neurological Surgery and principal investigator of the trial. Based on the preliminary findings, a larger phase 2 study is planned for 2007.
The trial results were presented last week in Orlando, Fla., during a meeting sponsored by the Society of Neuro-Oncology.
Copyright 2006 by United Press International
Related stories:
Nano vaccine for hepatitis B shows promise for third world
Chronic hepatitis B infects 400 million people worldwide, many of them children. Even with three effective vaccines available, hepatitis B remains a stubborn, unrelenting health problem, especially in Africa and other developing areas. The disease and its complications cause an estimated 1 million deaths globally each year.
Vaccine may double survival in patients with deadly brain tumors
A vaccine aimed at inducing immunity to the most common and deadly type of brain tumor may stave off recurrence and more than double survival in patients, according to a new study led by researchers in Duke’s Preston Robert Tisch Brain Tumor Center.
Common virus may serve as target for vaccine in fight against deadly brain tumors
By targeting a common virus, doctors may be able to extend the lives of patients diagnosed with the most prevalent and deadly type of brain tumor, according to a study led by researchers in Duke’s Preston Robert Tisch Brain Tumor Center.
Alzheimer's vaccine clears plaque but has little effect on learning and memory impairment
A promising vaccine being tested for Alzheimer's disease does what it is designed to do -- clear beta-amyloid plaques from the brain -- but it does not seem to help restore lost learning and memory abilities, according to a University of California, Irvine study.
China's biotech industry: An Asian dragon is growing
Backed by a government intent on promoting innovation and fuelled by the “brain gain” of talented scientists and entrepreneurs returning from abroad, China’s health biotech industry only needs a more favourable investment climate to emerge as a global force in the production of therapies and medicines – both new and low-cost generics – experts say in a new study.
An Alzheimer's vaccine?
Could a new vaccine be the key to stopping Alzheimer’s disease? A new research study from the Oklahoma Medical Research Foundation (OMRF) shows that immunization could offer a way to blunt or even prevent the deadly, memory-robbing disease.
Common virus may help doctors treat deadly brain tumors
A common human virus may prove useful in attacking the deadliest form of brain tumors, according to a study by researchers at Duke’s Preston Robert Tisch Brain Tumor Center. The researchers said the finding is an important step in developing a vaccine that can attack the tumors by enlisting the help of the body’s immune system.
Mayo Clinic tests novel vaccine for aggressive brain tumors
A vaccine that has significantly increased life expectancy in early tests of patients with glioblastoma multiforme (GBM) − the most common, most aggressive form of brain cancer in adults − is now being offered through a clinical trial at Mayo Clinic in Jacksonville.